Biotechnology companies from Canada have joined a chorus of their global counterparts to rail against the U.S. Food and Drug Administration’s tardiness in approving new drugs.

Products by companies such as Que-based Labopharm Inc. and B.C.-based Cardiome Pharma Corp. have been delayed in the key U.S. market for months, chipping into their revenue and waylaying their plans.

The FDA has blamed a severely depleted staff and dwindling funds for the holdups in approving treatments, while it also deals with an overly cautious U.S. Congress that is keen to turn over every stone.

Latest From ...